Drugs Made In America Acquisition (DMAAR) EBIT (2025)

Drugs Made In America Acquisition (DMAAR) posted EBIT of -$2.1 million for Q4 2025, down 692.36% on a QoQ basis from -$263703.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) EBIT (2025) Analysis & Trends

Drugs Made In America Acquisition's EBIT history runs 1 years deep, the most recent figure standing at -$2.1 million for Q4 2025.

Quarterly EBIT changed N/A year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.8 million (changed N/A YoY) and the FY2025 annual result came in at -$2.8 million, down 906.28% from the prior year.
EBIT was -$2.1 million for Q4 2025 at Drugs Made In America Acquisition, down from -$263703.0 in the prior quarter.
Across five years, EBIT topped out at -$131919.0 in Q2 2025 and bottomed at -$2.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-	-126,910.00
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-	-394,142.00
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-	-219,150.00
4	Dynamix	178.78 Mn	178.78 Mn	-	-731,801.00
5	Hallmark Venture	103.01 Mn	102.76 Mn	-	-38,571.00
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-	-1.35 Mn
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-	-318,676.00
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-	-399,870.00
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-	-2.09 Mn

Download Data